Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · November 10, 2016

Randomized Trial of Buparlisib and Paclitaxel to Treat HER2− Advanced Breast Cancer

Annals of Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
A Randomized Adaptive Phase II/III Study of Buparlisib, a Pan-Class I PI3K Inhibitor, Combined With Paclitaxel for the Treatment of HER2− Advanced Breast Cancer (BELLE-4)
Ann. Oncol 2016 Nov 01;[EPub Ahead of Print], M Martín, A Chan, L Dirix, J O'Shaughnessy, R Hegg, A Manikhas, M Shtivelband, P Krivorotko, N Batista López, M Campone, M Ruiz Borrego, QJ Khan, JT Beck, M Ramos Vázquez, P Urban, S Goteti, E Di Tomaso, C Massacesi, S Delaloge

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading